View Item 

Show simple item record

Systolic blood pressure and cardiovascular outcomes in heart failure with preserved ejection fraction: an analysis of the TOPCAT trial
dc.contributor.authorSelvaraj, Senthil
dc.contributor.authorClaggett, Brian
dc.contributor.authorShah, Sanjiv J.
dc.contributor.authorAnand, Inder
dc.contributor.authorRouleau, Jean L.
dc.contributor.authorDesai, Akshay S.
dc.contributor.authorLewis, Eldrin F.
dc.contributor.authorPitt, Bertram
dc.contributor.authorSweitzer, Nancy K.
dc.contributor.authorPfeffer, Marc A.
dc.contributor.authorSolomon, Scott D.
dc.date.accessioned2018-04-04T18:53:25Z
dc.date.available2019-05-13T14:45:26Zen
dc.date.issued2018-03
dc.identifier.citationSelvaraj, Senthil; Claggett, Brian; Shah, Sanjiv J.; Anand, Inder; Rouleau, Jean L.; Desai, Akshay S.; Lewis, Eldrin F.; Pitt, Bertram; Sweitzer, Nancy K.; Pfeffer, Marc A.; Solomon, Scott D. (2018). "Systolic blood pressure and cardiovascular outcomes in heart failure with preserved ejection fraction: an analysis of the TOPCAT trial." European Journal of Heart Failure 20(3): 483-490.
dc.identifier.issn1388-9842
dc.identifier.issn1879-0844
dc.identifier.urihttps://hdl.handle.net/2027.42/142943
dc.publisherJohn Wiley & Sons, Ltd
dc.subject.otherHeart failure with preserved ejection fraction
dc.subject.otherHeart failure hospitalization
dc.subject.otherSpironolactone
dc.subject.otherBlood pressure
dc.titleSystolic blood pressure and cardiovascular outcomes in heart failure with preserved ejection fraction: an analysis of the TOPCAT trial
dc.typeArticleen_US
dc.rights.robotsIndexNoFollow
dc.subject.hlbsecondlevelCardiovascular Medicine
dc.subject.hlbtoplevelHealth Sciences
dc.description.peerreviewedPeer Reviewed
dc.description.bitstreamurlhttps://deepblue.lib.umich.edu/bitstream/2027.42/142943/1/ejhf1060.pdf
dc.description.bitstreamurlhttps://deepblue.lib.umich.edu/bitstream/2027.42/142943/2/ejhf1060_am.pdf
dc.identifier.doi10.1002/ejhf.1060
dc.identifier.sourceEuropean Journal of Heart Failure
dc.identifier.citedreferenceMeredith PA, Ostergren J, Anand I, Puu M, Solomon SD, Michelson EL, Olofsson B, Granger CB, Yusuf S, Swedberg K, Pfeffer MA, McMurray JJ. Clinical outcomes according to baseline blood pressure in patients with a low ejection fraction in the CHARM (Candesartan in Heart Failure: Assessment of Reduction in Mortality and Morbidity) Program. J Am Coll Cardiol 2008; 52: 2000 – 2007.
dc.identifier.citedreferenceYusuf S, Pfeffer MA, Swedberg K, Granger CB, Held P, McMurray JJ, Michelson EL, Olofsson B, Ostergren J; CHARM Investigators and Committees. Effects of candesartan in patients with chronic heart failure and preserved left‐ventricular ejection fraction: the CHARM‐Preserved Trial. Lancet 2003; 362: 777 – 7781.
dc.identifier.citedreferenceMassie BM, Carson PE, McMurray JJ, Komajda M, McKelvie R, Zile MR, Anderson S, Donovan M, Iverson E, Staiger C, Ptaszynska A; I‐PRESERVE Investigators. Irbesartan in patients with heart failure and preserved ejection fraction. N Engl J Med 2008; 359: 2456 – 2467.
dc.identifier.citedreferencePitt B, Pfeffer MA, Assmann SF, Boineau R, Anand IS, Claggett B, Clausell N, Desai AS, Diaz R, Fleg JL, Gordeev I, Harty B, Heitner JF, Kenwood CT, Lewis EF, O’Meara E, Probstfield JL, Shaburishvili T, Shah SJ, Solomon SD, Sweitzer NK, Yang S, McKinlay SM; TOPCAT Investigators. Spironolactone for heart failure with preserved ejection fraction. N Engl J Med 2014; 370: 1383 – 1392.
dc.identifier.citedreferenceCleland JG, Tendera M, Adamus J, Freemantle N, Polonski L, Taylor J; PEP‐CHF Investigators. The perindopril in elderly people with chronic heart failure (PEP‐CHF) study. Eur Heart J 2006; 27: 2338 – 2345.
dc.identifier.citedreferenceShah SJ, Kitzman DW, Borlaug BA, van Heerebeek L, Zile MR, Kass DA, Paulus WJ. Phenotype‐specific treatment of heart failure with preserved ejection fraction: a multiorgan roadmap. Circulation 2016; 134: 73 – 90.
dc.identifier.citedreferenceGroup SR, Wright JT, Williamson JD, Whelton PK, Snyder JK, Sink KM, Rocco MV, Reboussin DM, Rahman M, Oparil S, Lewis CE, Kimmel PL, Johnson KC, Goff DC, Jr., Fine LJ, Cutler JA, Cushman WC, Cheung AK, Ambrosius WT. A randomized trial of intensive versus standard blood‐pressure control. N Engl J Med 2015; 373: 2103 – 2116.
dc.identifier.citedreferenceYancy CW, Jessup M, Bozkurt B, Butler J, Casey DE, Jr., Colvin MM, Drazner MH, Filippatos GS, Fonarow GC, Givertz MM, Hollenberg SM, Lindenfeld J, Masoudi FA, McBride PE, Peterson PN, Stevenson LW, Westlake C. 2017 ACC/AHA/HFSA focused update of the 2013 ACCF/AHA Guideline for the management of heart failure: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Failure Society of America. Circulation 2017; 136: e137 – e161.
dc.identifier.citedreferenceLam CS, Shah AM, Borlaug BA, Cheng S, Verma A, Izzo J, Oparil S, Aurigemma GP, Thomas JD, Pitt B, Zile MR, Solomon SD. Effect of antihypertensive therapy on ventricular‐arterial mechanics, coupling, and efficiency. Eur Heart J 2013; 34: 676 – 683.
dc.identifier.citedreferencePfeffer MA, Claggett B, Assmann SF, Boineau R, Anand IS, Clausell N, Desai AS, Diaz R, Fleg JL, Gordeev I, Heitner JF, Lewis EF, O’Meara E, Rouleau JL, Probstfield JL, Shaburishvili T, Shah SJ, Solomon SD, Sweitzer NK, McKinlay SM, Pitt B. Regional variation in patients and outcomes in the Treatment of Preserved Cardiac Function Heart Failure With an Aldosterone Antagonist (TOPCAT) trial. Circulation 2015; 131: 34 – 42.
dc.identifier.citedreferenceDesai AS, Lewis EF, Li R, Solomon SD, Assmann SF, Boineau R, Clausell N, Diaz R, Fleg JL, Gordeev I, McKinlay S, O’Meara E, Shaburishvili T, Pitt B, Pfeffer MA. Rationale and design of the treatment of preserved cardiac function heart failure with an aldosterone antagonist trial: a randomized, controlled study of spironolactone in patients with symptomatic heart failure and preserved ejection fraction. Am Heart J 2011; 162: 966 – 972.e10.
dc.identifier.citedreferencePfeffer MA, Pitt B, McKinlay SM. Spironolactone for heart failure with preserved ejection fraction. N Engl J Med 2014; 371: 181 – 182.
dc.identifier.citedreferenceSolomon SD, Claggett B, Lewis EF, Desai A, Anand I, Sweitzer NK, O’Meara E, Shah SJ, McKinlay S, Fleg JL, Sopko G, Pitt B, Pfeffer MA; TOPCAT Investigators. Influence of ejection fraction on outcomes and efficacy of spironolactone in patients with heart failure with preserved ejection fraction. Eur Heart J 2016; 37: 455 – 462.
dc.identifier.citedreferenceAnand IS, Rector TS, Kuskowski M, Thomas S, Holwerda NJ, Cohn JN. Effect of baseline and changes in systolic blood pressure over time on the effectiveness of valsartan in the Valsartan Heart Failure Trial. Circ Heart Fail 2008; 1: 34 – 42.
dc.identifier.citedreferenceAnand IS, Tam SW, Rector TS, Taylor AL, Sabolinski ML, Archambault WT, Adams KF, Olukotun AY, Worcel M, Cohn JN. Influence of blood pressure on the effectiveness of a fixed‐dose combination of isosorbide dinitrate and hydralazine in the African‐American Heart Failure Trial. J Am Coll Cardiol 2007; 49: 32 – 39.
dc.identifier.citedreferenceCooper‐DeHoff RM, Gong Y, Handberg EM, Bavry AA, Denardo SJ, Bakris GL, Pepine CJ. Tight blood pressure control and cardiovascular outcomes among hypertensive patients with diabetes and coronary artery disease. JAMA 2010; 304: 61 – 68.
dc.identifier.citedreferenceOvbiagele B, Diener HC, Yusuf S, Martin RH, Cotton D, Vinisko R, Donnan GA, Bath PM, Investigators P. Level of systolic blood pressure within the normal range and risk of recurrent stroke. JAMA 2011; 306: 2137 – 2144.
dc.identifier.citedreferenceBohm M, Young R, Jhund PS, Solomon SD, Gong J, Lefkowitz MP, Rizkala AR, Rouleau JL, Shi VC, Swedberg K, Zile MR, Packer M, McMurray JJV. Systolic blood pressure, cardiovascular outcomes and efficacy and safety of sacubitril/valsartan (LCZ696) in patients with chronic heart failure and reduced ejection fraction: results from PARADIGM‐HF. Eur Heart J 2017; 38: 1132 – 1143.
dc.identifier.citedreferenceEdelmann F, Wachter R, Schmidt AG, Kraigher‐Krainer E, Colantonio C, Kamke W, Duvinage A, Stahrenberg R, Durstewitz K, Loffler M, Dungen HD, Tschope C, Herrmann‐Lingen C, Halle M, Hasenfuss G, Gelbrich G, Pieske B; Aldo‐DHF Investigators. Effect of spironolactone on diastolic function and exercise capacity in patients with heart failure with preserved ejection fraction: the Aldo‐DHF randomized controlled trial. JAMA 2013; 309: 781 – 791.
dc.identifier.citedreferenceJhund PS, Claggett B, Packer M, Zile MR, Voors AA, Pieske B, Lefkowitz M, Shi V, Bransford T, McMurray JJ, Solomon SD. Independence of the blood pressure lowering effect and efficacy of the angiotensin receptor neprilysin inhibitor, LCZ696, in patients with heart failure with preserved ejection fraction: an analysis of the PARAMOUNT trial. Eur J Heart Fail 2014; 16: 671 – 677.
dc.identifier.citedreferenceShah AM, Claggett B, Sweitzer NK, Shah SJ, Deswal A, Anand IS, Fleg JL, Pitt B, Pfeffer MA, Solomon SD. Prognostic importance of changes in cardiac structure and function in heart failure with preserved ejection fraction and the impact of spironolactone. Circ Heart Fail 2015; 8: 1052 – 1058.
dc.identifier.citedreferencePaulus WJ, Tschope C. A novel paradigm for heart failure with preserved ejection fraction: comorbidities drive myocardial dysfunction and remodeling through coronary microvascular endothelial inflammation. J Am Coll Cardiol 2013; 62: 263 – 271.
dc.owningcollnameInterdisciplinary and Peer-Reviewed


Files in this item

Name:
ejhf1060.pdf
Size:
522.4KB
Format:
PDF
View/Open
Name:
ejhf1060_am.pdf
Size:
941.2KB
Format:
PDF
View/Open

Show simple item record

Remediation of Harmful Language

The University of Michigan Library aims to describe library materials in a way that respects the people and communities who create, use, and are represented in our collections. Report harmful or offensive language in catalog records, finding aids, or elsewhere in our collections anonymously through our metadata feedback form. More information at Remediation of Harmful Language.

Accessibility

If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.